Document:

exv10w9

 

Exhibit 10.9

CONFIDENTIAL

SETTLEMENT AND

PATENT LICENSE AGREEMENT1

     THIS AGREEMENT (the “Agreement”) is made as of this 28th day of February, 2006 (the
“Effective Date”) by and between NetRatings, Inc., a Delaware corporation, with offices at 120 West
45th Street, New York, New York 10036 (“NetRatings”), and Omniture, Inc., a Delaware
corporation, with offices at 550 East Timpanogos Circle, Orem, Utah 84097 (“Omniture” or
“Licensee”) (NetRatings and Licensee collectively, the “Parties”).

WITNESSETH:

     WHEREAS, NetRatings is the sole and exclusive owner or joint owner of certain patents and
patent applications, as farther identified herein;

     WHEREAS, the Parties are presently engaged in litigation in the United States District Court,
District of Delaware, captioned NetRatings, Inc. v. Omniture, Inc., Civil Action No. 05-313-GMS
(the “Action”);

     WHEREAS, the Parties wish to resolve and settle the Action and all disputes that are the
subject matter of the Action; and

     WHEREAS, as part of the settlement of the Action, NetRatings wishes to grant to Licensee, and
Licensee wishes to receive, a license under the aforementioned patents of NetRatings pursuant to
the terms and subject to the conditions of this Agreement.

     NOW, THEREFORE, in consideration of the mutual promises and covenants herein contained, the
Parties agree as follows:

     1. DEFINITIONS

     The capitalized terms in this Agreement which are not defined in the text of the Agreement
shall have the meanings set forth in this Section 1. In addition, the existence or scope
of any defined term in this Agreement shall not constitute or be deemed to be the belief on the
part of NetRatings that the NetRatings Patents or any claims therein are in any way limited in
scope or to application or enforcement in any particular field(s) of use.

          1.1 “Change of Control Event” means the closing of a sale to or acquisition by a person or
entity (“Purchaser”), whether by merger, consolidation, reorganization or other similar transaction
or series of related transactions, of (i) all or substantially all of the assets of the Licensee;

 

			
	1	 	Certain provisions of this agreement marked
with a [ * ] have been omitted based upon a request for confidential treatment,
and such provisions have been filed separately with the Securities and Exchange
Commission pursuant to the application for confidential treatment.

 

 

or (ii) fifty percent (50%) or more of the combined voting power of Licensee’s then
outstanding securities. For the avoidance of doubt, a Change of Control Event shall not include a
public or private offering of Omniture securities, unless as a result of such offering a person or
entity acquires fifty percent (50%) or more of the combined voting power of Omniture’s securities
outstanding immediately following such offering.

          1.2 “Licensee Customer” shall mean any person or entity who, with express authorization from
Licensee or a Licensee Provider, purchases, leases, licenses, subscribes to or uses any Licensed
Product only for such person’s or entity’s own use internally or in monitoring or tracking the use
or access of computer resources delivered by such person or entity over a network, and not for the
purpose of providing the Licensed Product or any service depending thereon to a third party.

          1.3 “Licensee Provider” shall mean any person or entity who, with express authorization from
and on behalf of Licensee (including without limitation OEM’s, resellers and distributors),
manufactures or develops any Licensed Product for Licensee, or offers for sale, sells, imports,
exports, resells, licenses, combines or distributes to Licensee Customers any Licensed Product
whether on a standalone basis or in combination with its own products or services, including, but
not limited to, for the purpose of providing the Licensed Product or any service depending thereon
to a third party.

          1.4 “Licensed Products” shall mean any products, technology or services (whether in whole or
in part, or any portion thereof, and whether pursuant to sale, license, subscription service or
otherwise) that are manufactured, made or developed by or for Omniture, or that are used, licensed,
marketed, offered for sale, distributed, exported, imported or sold by Omniture, directly or
indirectly, except as provided in Section 2.2. Licensed Products commercially released as
of the Effective Date are listed on Schedule B hereto. Except to the extent permitted by
Section 15.1(ii). Licensed Products shall not include any product, technology or service
developed by and for an entity other than Omniture and which are sold by third parties.

          1.5 “Licensee’s Revenue” shall mean Licensee’s gross consolidated revenues from the
manufacture, development, design, sale, offer for sale, resale, import, export, integration,
hosting, leasing, licensing or distributing of products, technology and/or services, including but
not limited to revenue received from all Licensee Customers and Licensee Providers, less, sales,
VAT, excise, or similar taxes, discounts and allowances actually shown on an applicable invoice.
No costs shall be deducted from Licensee’s Revenue. Licensee’s Revenue shall be deemed to have
occurred when such revenue is recognized by Licensee in accordance with generally accepted
accounting principles consistently applied.

          1.6 “NetRatings Patents” shall mean all United States and foreign issued patents and pending
patent applications owned or controlled by NetRatings as of the Effective Date, including the
patents and patent applications identified on Schedule A attached hereto, which schedule
NetRatings agrees to supplement within thirty (30) days of the Effective Date. In addition, the
NetRatings Patents shall include any foreign counterparts, and United States or foreign patents
issuing as a divisional, continuation, continuation-in-part, reissue, reexamination, renewal or
extension of any of the foregoing patents and any pending patent applications, as well as any and
all

-2-

 

other present or future United States or foreign patents or patent applications that claim
priority to any of the above.

          1.7 “Omniture Patents” shall mean all United States and foreign issued patents, if any, and
pending patent applications owned or controlled by Omniture as of the Effective Date, including the
patents and patent applications identified on Schedule C attached hereto, which schedule
Omniture agrees to supplement within thirty (30) days of the Effective Date, and any United States
or foreign patents issuing as a divisional, continuation, continuation-in-part, reissue,
reexamination, renewal or extension of any of the foregoing patents and patent applications.

          1.8 “Term” shall mean the period commencing as of the Effective Date and continuing to and
including the date on which the last remaining NetRatings Patent listed in Schedule A (as
will be supplemented by NetRatings within thirty (30) days pursuant to Section 1.6, or as
may be supplemented by NetRatings thereafter upon a showing that a patent or application was
inadvertently omitted from Schedule A) expires, unless earlier terminated in accordance
with Section 10.

          1.9 “Web Analytics” shall mean [ * ].

     2. LICENSE

          2.1 Grant of License to Licensee. Subject to Section 2.2, NetRatings hereby
grants to Licensee, subject to the terms and conditions of this Agreement, a limited, irrevocable
(except as provided in Section 10), non-exclusive, non-transferable (except as provided in
Section 15), royalty-bearing, world-wide license under the NetRatings Patents during the
Term to make (including the right to practice methods, processes and procedures), have made, use,
license, lease, sell, offer for sale, market, distribute, export and import the Licensed Products
(the “License”).

          2.2 Exclusions. Notwithstanding anything in this Agreement to the contrary, Licensee
expressly acknowledges and agrees that the License granted under this Agreement does not permit the
Licensee (or therefore any Licensee Customers or Licensee Providers) the right to:

               (i) [ * ] For purposes of this Section 2.2(i), an “affiliate” of a “person or entity”
means any other person or entity that, directly or indirectly through one or more intermediaries,
controls or is controlled by or is under common control with such “person or entity.”

               (ii) [ * ]

          2.3 Reservation of Rights. Any and all rights not expressly granted to Licensee in
this Agreement with respect to the NetRatings Patents, including, without limitation, the rights
reserved under Section 2.2 to practice the NetRatings Patents and the right to enforce the
NetRatings Patents against third parties and collect royalties and/or damages in connection
therewith, are hereby reserved and retained exclusively by NetRatings.

          2.4 Sublicense Rights. Licensee may grant to Licensee Customers a limited,
non-exclusive, non-transferable, written sublicense under the License solely for the purpose of
allowing such entities to purchase or use the Licensed Products in accordance with Section
1.2. In

-3-

 

addition, Licensee may grant to Licensee Providers a limited, nonexclusive, non-transferable,
written sublicense under the License solely for the purpose of allowing such entities to
manufacture or develop any Licensed Product for Licensee, or offer for sale, sell, import, export,
resell, license, combine or distribute to Licensee Customers any Licensed Product whether on a
standalone basis or in combination with its own products or services, including, but not limited
to, for the purpose of providing the Licensed Product or any service depending thereon to a third
party. Such sublicenses shall in no event apply to products, services or technology of a Licensee
Customer or Licensee Provider which, without the Licensed Products, infringes any independent claim
of any NetRatings Patents. Other than as expressly provided by this Section 2.4, no other
sublicenses of any kind may be granted under this Agreement, and any such sublicenses shall be null
and void. Any sublicenses granted hereunder are only valid and in effect when and if the License
is valid and in effect.

          2.5 Markings and Samples. Licensee shall fully comply with the patent marking
provisions of the United States or other applicable patent laws. In furtherance of the foregoing,
Licensee will clearly label the Licensed Products with identifying numbers of any issued NetRatings
Patents, specifying that the Licensed Products are licensed under such NetRatings Patents. As may
be requested from time to time, but in no event more than once each calendar year of the Term,
Licensee shall submit to NetRatings five (5) samples of each of the Licensed Products or such other
evidence, including screen captures, as will be reasonably sufficient to show that the marking
requirements of this Section 2.6 are being fulfilled. Neither the marking of any Licensed
Product pursuant to this Agreement or this Section 2 shall be deemed to constitute an
admission by Licensee that the Licensed Products are covered by the NetRatings Patents.

     3. PAYMENT OF ROYALTIES

          3.1 Royalty Fees.

               (i) Initial Royalty. As partial consideration for the settlement of the Action and
the License granted under this Agreement, and regardless of whether any additional payments are
paid under Section 3.1 of this Agreement, Licensee shall pay ten-million U.S. dollars
($10,000,000) to NetRatings (the “Initial Royalty”) as follows: (1) within three (3) business days
from the date on which Licensee executes this Agreement and receives an original of this Agreement,
including all Exhibits (including the stipulations required under Section 9), that has been
fully executed by a duly authorized representative of NetRatings, Licensee shall pay one-million
five-hundred thousand U.S. dollars ($1,500,000) to NetRatings; (2) no later than June 15, 2006,
Licensee shall pay one-million five-hundred thousand U.S. dollars ($1,500,000) to NetRatings; (3)
no later than September 15, 2006, Licensee shall pay one-million five-hundred thousand U.S. dollars
($1,500,000) to NetRatings; (4) on or before December 15,2006, Licensee shall pay one-million
five-hundred thousand U.S. dollars ($1,500,000) to NetRatings; (5) on or before March 15, 2007,
Licensee shall pay one-million U.S. dollars ($1,000,000) to NetRatings; (6) on or before June 15,
2007, Licensee shall pay one-million U.S. dollars ($1,000,000) to NetRatings; (7) on or before
September 15, 2007, Licensee shall pay one-million U.S. dollars ($1,000,000) to NetRatings; and (8)
on or before December 15, 2007, Licensee shall pay one-million U.S. dollars ($1,000,000) to
NetRatings.

-4-

 

               (ii) Additional Royalty. As further consideration for the License granted under this
Agreement, and in addition to the other payments required pursuant to Section 3.1 of this
Agreement, Licensee will pay NetRatings an additional royalty, in the aggregate not to exceed
four-million U.S. dollars ($4,000,000) (the “Additional Royalty”), which Additional Royalty shall
be required to be paid only if and when: (1) Licensee completes an initial public offering of its
securities, in which case Licensee shall pay NetRatings four-million U.S. dollars ($4,000,000)
(minus any other payments previously made under this Section 3.1(ii)) within five (5)
business days of the closing of the initial public offering; (2) a Change of Control Event occurs,
in which case Licensee shall pay NetRatings four-million U.S. dollars ($4,000,000) (minus any other
payments previously made under this Section 3.1(ii)) within five (5) business days of such
Change of Control Event; and (3) for calendar year 2008, and each calendar year thereafter,
Licensee’s Revenue equals or exceeds sixty-million U.S. Dollars ($60,000,000), in which case
Licensee shall pay NetRatings two-million U.S. dollars ($2,000,000) on or before January 30 of the
calendar year immediately following the calendar year in which Licensee’s Revenue equaled or
exceeded sixty-million U.S. dollars ($60,000,000), up to a total of four-million U.S. dollars
($4,000,000) (minus any other payments previously made under this Section 3.1(ii)).

               (iii) Licensee Provider Royalties. As further consideration for the License granted
under this Agreement, and in addition to the other payments required pursuant to Section
3.1 of this Agreement, in the event Licensee’s revenue for any given calendar year during the
Term from any single Licensee Provider listed in Schedule F to this agreement (including
affiliates and subsidiaries of such Licensee Provider as of the Effective Date) equals or exceeds [
* ], then, on or before January 30 of the calendar year immediately following such given calendar
year, Licensee shall pay an amount equal to [ * ] (the “Licensee Provider Royalty”). During the
Term, Licensee shall make such annual Licensee Provider Royalty payments, if any, up to a total of
[ * ] in the aggregate, at which time no additional Licensee Provider Royalties will become due.
For purposes of this Section 3.1(iii), Licensee’s revenue attributable to any single
Licensee Provider shall be determined in the same manner as Licensee’s Revenues are determined for
Licensee as defined in Section 1.5 of this Agreement.

               (iv) Licensee Acquisition Royalties. As further consideration for the License granted
under this Agreement, and in addition to the other payments required pursuant to Section
3.1 of this Agreement, and subject to Section 3.2 below, in the event that, during the
Term, Licensee acquires, whether by merger, consolidation, reorganization or other similar
transaction or series of transactions, all or substantially all the technology, customers, or other
assets of an entity or fifty percent (50%) or more of the combined voting power of an entity’s then
outstanding securities (in either case, the entity being referred to herein as the “Acquired
Entity”), then, within thirty (30) business days following the closing date of any such
transaction, Licensee will either pay NetRatings (1) an additional royalty of [ * ], or (2) an
additional royalty of [ * ] (either of the foregoing royalties referred to as a “Licensee
Acquisition Royalty”). For purposes of this Section 3.1(iv), the [ * ]. Notwithstanding
the foregoing, Licensee shall not be obligated to pay the Licensee Acquisition Royalties for any
transaction if and only if (1) Licensee has paid (regardless of the type of consideration) less
than [ * ] for such Acquired Entity or the assets or securities thereof in a single transaction or
in any series of transactions, or (2) the Acquired Entity already has a license from NetRatings
under the NetRatings Patents which covers the acquired technology, customers or other

-5-

 

assets of the Acquired Entity or (3) Licensee’s royalty payment obligations have terminated
prior to the closing date of such transaction pursuant to Section 3.2.

          3.2 Termination of Royalty Obligations. In the event that, and only in the event
that, every claim of every one of NetRatings’ U.S. Patent Nos. 5,675,510; 5,796,952; 6,115,680;
6,108,637; 6,138,155; 6,643,696; 6,763,386 and any additional NetRatings Patent asserted against at
least one accused infringer in any litigation action currently pending or started within six (6)
months of the Effective Date, is determined to be invalid or unenforceable by a final, unappealed
decision of a court having competent jurisdiction and authority to issue such a holding or by the
Federal Circuit Court of Appeals, whichever is earlier, then the payment obligations set forth in
Section 3.1 shall be terminated as of the date of such decision, and from that date
forward, no further Initial or Additional Royalty payments will be due. The termination of the
payments pursuant to this Section 3.2 shall not entitle Licensee to a refund of any
payments previously made. Licensee agrees not to contest the validity or enforceability of any of
the NetRatings Patents or in any way assist any other entity in contesting the validity or
enforceability of any of the NetRatings Patents, except that Licensee may contest the validity or
enforceability of any NetRatings Patent which NetRatings asserts against Licensee in an action.
Licensee further agrees that the termination of any of the royalty payments pursuant to this
Section 3.2 shall not be effective in the event of a breach of Licensee’s agreement not to
so contest or assist in contesting the validity or enforceability of any of the NetRatings Patents.

          3.3 Method of Payment. Unless otherwise specified in writing by NetRatings, all
payments to be made by Licensee under this Agreement shall be made by wire transfer of funds to the
account of NetRatings as set forth in Exhibit B hereto.

          3.4 Interest on Late Payments. Late payments shall incur at the prime interest rate,
as reported by the Wall Street Journal, plus one percent (1%) per month from the date such payments
were originally due hereunder or the highest rate allowable under applicable law (whichever is
less).

          3.5 Royalty Statements. Unless or until Licensee’s obligation to pay the Additional
Royalty and Licensee Provider Royalty is fully satisfied or has terminated, then, on or before
January 30th of each calendar year, Licensee shall provide NetRatings with written
statements of Licensee’s Revenue in the form annexed hereto as Schedule D. Within thirty
(30) business days of any acquisition by Licensee pursuant to Section 3.1(iv). Licensee
shall provide NetRatings with a written statement of the applicable [ * ]. Such royalty statements
shall be certified as accurate by a duly authorized officer of Licensee. The receipt or acceptance
by NetRatings of any royalty statement or payment shall not prevent NetRatings from subsequently
challenging the validity or accuracy of such statement or payment.

     4. RECORD INSPECTION AND AUDIT

          4.1 Right To Inspect and Audit. Unless or until Licensee’s obligation to pay the
Additional Royalty and Licensee Provider Royalty is fully satisfied or has terminated, NetRatings
shall have the right, upon reasonable notice to Licensee, up to one (1) time during each calendar
year during the Term and for three (3) years thereafter, to audit Licensee’s books and records
relevant to

-6-

 

the calculation of Licensee’s Revenue. In addition, within ninety (90) days of the effective
date of an acquisition under Section 3.1(iv), NetRatings shall have the right, upon
reasonable notice to Licensee, up to one (1) time with respect to any acquisition and to be
conducted within three (3) months from the date of receipt of notice regarding such acquisition, to
audit Licensee’s books and records relevant to the revenues of any Acquired Entity for which
Licensee Acquisition Royalties maybe due pursuant to Section 3.1(iv). Any audits described
herein will be performed by an independent accounting firm that is mutually agreed upon by
NetRatings and Licensee, provided that such accounting firm agrees in writing to maintain the
confidentiality of such books and records.

     5. COVENANT NOT TO SUE

          5.1 Omniture Covenant to NetRatings. Omniture and its subsidiaries hereby covenant
and agree that they will not bring suit against NetRatings, its subsidiaries, authorized customers,
manufacturers, distributors, and resellers, for infringement of any Omniture Patent based on the
manufacturing, making (including the right to practice methods, processes and procedures), having
made, using, leasing, selling, offering for sale, marketing, distributing, exporting and importing
of (i) any NetRatings product, service and/or technology commercially released or which NetRatings
can show were under development prior to or as of the Effective Date but only if each such
NetRatings product under development is released as a standard product within twelve (12) months of
the Effective Date (“NetRatings Original Versions”), and future versions of the NetRatings Original
Versions which contain no more than patches to, bug fixes of, minor enhancements or modifications
of, or minor updates or upgrades of the NetRatings Original Versions, except for any new features
or functionality added to NetRatings Original Versions which infringe an Omniture Patent that did
not already cover the NetRatings Original Versions; and (ii) any product, service and/or technology
acquired by NetRatings from a third party, including by acquisition of such third party, provided
that such acquired product, service and/or technology does not infringe an Omniture Patent which
did not already cover the NetRatings Original Versions. The foregoing covenant is personal to
NetRatings and its subsidiaries and is not transferable or assignable [ * ].

     6. REPRESENTATIONS AND WARRANTIES

          6.1 Representations and Warranties of the Parties. The parties represent and warrant
to each other that: (i) it and/or its subsidiaries are the owner or joint owner (as specifically
identified on Schedule A) of the right, title, and interest in and to the NetRatings
Patents or the Omniture Patents (as applicable); and (ii) it has the right and power to enter into
this Agreement and, with respect to NetRatings, it has the power to grant the License granted
herein. Licensee represents and warrants that the information in Schedule E is true and
accurate. Each party acknowledges that the foregoing representations and warranties made by the
other party constitute a material part of the consideration inducing each party to enter into this
Agreement.

          6.2 Limitations on Warranties. Nothing in this Agreement shall be construed as: (i)
representing the scope of any claims of the NetRatings Patents or the Omniture Patents; or (ii)
representing that the sale or use of such products or services encompassed by any of the claims set
forth in one or more claims of the NetRatings Patents or the Omniture Patents will be free of
infringement of any other intellectual property rights.

-7-

 

          6.3 DISCLAIMER OF WARRANTIES. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS
SECTION 6, EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING,
WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
NON-INFRINGEMENT.

     7. LIMITATIONS OF LIABILITY

     EXCEPT WITH RESPECT TO CLAMS RELATED TO EACH PARTY’S NONDISCLOSURE OBLIGATIONS UNDER
SECTION 11, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INDIRECT,
INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING ANY LOST PROFITS, EXEMPLARY OR SPECIAL DAMAGES,
HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, ARISING OUT OF THIS AGREEMENT OR OTHERWISE. IN ALL
EVENTS, EACH PARTY’S TOTAL LIABILITY IN THE AGGREGATE UNDER THIS AGREEMENT (EXCEPT WITH RESPECT TO
LICENSEE’S ROYALTY OBLIGATIONS AND WITH CLAIMS RELATED TO EACH PARTY’S NONDISCLOSURE OBLIGATIONS
UNDER SECTION 11) IS LIMITED TO AND SHALL NOT EXCEED FIVE HUNDRED THOUSAND U.S. DOLLARS (US
$500,000), PLUS ANY ATTORNEYS’ FEES AND INTEREST WHICH MAY BE DUE UNDER THIS AGREEMENT OR UNDER
LAW. FOR THE AVOIDANCE OF DOUBT, NOTHING IN THIS SECTION 7 SHALL BE CONSTRUED TO LIMIT THE
LIABILITY OF LICENSEE RESULTING FROM LICENSEE’S MANUFACTURE, SALE OR USE OF ANY PRODUCTS OR
SERVICES OUTSIDE OF THE SCOPE OF THE LICENSE GRANTED HEREUNDER.

     8. RELEASES

          8.1 Release of Omniture. NetRatings and its subsidiaries, officers, directors and
employees hereby irrevocably release and discharge Licensee and its subsidiaries, officers,
directors, managers, members and employees from any actions, demands, claims, causes of action,
charges, judgments, damages and attorneys fees, including but not limited to all claims asserted in
the Action, or in connection with the NetRatings Patents, or which should have been brought in the
Action, whether known or unknown, suspected or unsuspected, in law or in equity, arising from or in
connection with the manufacture (including practicing methods, processes and procedures), use,
lease, license, sale, offer for sale, market, distribution, exportation or importation of the
Licensed Products from the beginning of time up to and including the Effective Date of this
Agreement. Nothing in this Section 8.1 is intended by NetRatings to release Licensee from
any of its obligations under this Agreement or from any liability of Licensee or any other person
for actions occurring after the Effective Date.

          8.2 Release of NetRatings. Licensee and its subsidiaries, officers, directors,
managers, members and employees hereby release and discharge NetRatings and its subsidiaries,
officers, directors and employees from any actions, demands, claims, causes of action, charges,
judgments, damages or attorneys fees, including but not limited to all claims asserted in the
Action, whether known or unknown, suspected or unsuspected, in law or in equity, arising from or in
connection with the Action or the Omniture Patents, or which should have been brought in the
Action, arising from or in connection with the manufacture (including practicing methods, processes

-8-

 

and procedures), use, lease, license, sale, offer for sale, market, distribution, exportation
or importation of any NetRatings’ product, service or technology from the beginning of time up to
and including the Effective Date of this Agreement. Nothing in this Section 8.2 is
intended by Omniture to release NetRatings from any of its obligations under this Agreement or from
any liability of NetRatings or any other person for actions occurring after the Effective Date.

     9. DISMISSAL OF THE ACTION

     Promptly upon execution of this Agreement by the Parties, the Parties shall cause their
respective legal counsel to execute a Stipulation of Dismissal With Prejudice under Rule 41 of the
Federal Rules of Civil Procedure dismissing the Action with prejudice. Each Party will bear its
own litigation costs and fees. The Stipulation of Dismissal will be in the form attached hereto as
Exhibit A.

     10. TERMINATION

     If either party breaches any material term or condition of this Agreement and fails to cure
such breach within thirty (30) days after receiving written notice of the breach, the non-breaching
party may terminate this Agreement on written notice at any time following the end of such thirty
(30) day period. Licensee’s failure to timely make a payment required under Section 3.1 of
this Agreement shall constitute a material breach by Licensee of the Agreement, except that
Licensee shall have sixty (60) days to cure such breach following receipt of written notice thereof
from NetRatings. If Licensee acts outside the scope of the license granted in Section 2.1
or fails to make any payment required in Section 3.1 of this Agreement and fails to cure
such action, or if Licensee fails to cure a material breach of Section 2.2(i), then the
License will be terminated and all of the payments set forth in Section 3.1 herein
(including both the Initial Royalty and the Additional Royalty) will be accelerated and deemed
immediately due and payable as of the date of such termination. In the event that the License is
terminated, the covenant not to sue as specified in Section 5 shall be terminated
concurrently.

     11. CONFIDENTIALITY

          11.1 Definition of Confidential Information. “Confidential Information” shall mean
any confidential technical data, trade secret, know-how or other confidential information disclosed
by any Party hereunder in writing, orally, or by drawing or other form and which shall be marked by
the disclosing party as “Confidential” or “Proprietary.” If such information is disclosed orally,
or through demonstration, in order to be deemed Confidential Information, it must be specifically
designated as being of a confidential nature at the time of disclosure and reduced in writing and
delivered to the receiving party within thirty (30) calendar days of such disclosure.

          11.2 Exceptions To Confidentiality. Notwithstanding the foregoing, Confidential
Information shall not include information which: (i) is known to the receiving party at the time of
disclosure or becomes known to the receiving party without breach of this Agreement; (ii) is or
becomes publicly known through no wrongful act of the receiving party or any subsidiary of the
receiving party; (iii) is rightfully received from a third party without restriction on disclosure;
(iv) is

-9-

 

independently developed by the receiving party or any of its subsidiary; or (v) is approved
for release upon a prior written consent of the disclosing party.

          11.3 Confidentiality Obligations. The receiving party agrees that it will not
disclose any Confidential Information to any third party and will not use Confidential Information
of the disclosing party for any purpose other than for the performance of the rights and
obligations hereunder during the Term of this Agreement and for a period of [ * ] thereafter,
without the prior written consent of the disclosing party. The receiving party further agrees that
Confidential Information shall remain the sole property of the disclosing party and that it will
take all reasonable precautions to prevent any unauthorized disclosure of Confidential Information
by its employees. No license shall be granted by the disclosing party to the receiving party with
respect to Confidential Information disclosed hereunder unless otherwise expressly provided herein.

          11.4 Return of Confidential Information. Upon the request of the disclosing party,
the receiving party will promptly return all Confidential Information furnished hereunder and all
copies thereof.

          11.5 Disclosure. Neither party shall disclose this Agreement or any of the terms
hereof to any third party without the prior written consent of the other party. This Agreement and
its terms shall be held in strict confidence by each party and shall constitute Confidential
Information. [ * ]. Further, based upon consultation with inside or outside legal counsel,
either party may disclose information concerning this Agreement as required by the rules, orders,
regulations, discovery requirements, subpoenas or directives of a court, government or governmental
agency (including without limitation the SEC). Prior to any such disclosure, either party will
promptly inform the other party of the scope of and basis for such disclosure. In the event either
party determines that this Agreement, or a portion thereof, is required to be filed with the SEC,
it will, if requested by the other party, seek confidential treatment for the portions of the
Agreement for which the other party requests such confidential treatment. Notwithstanding anything
to the contrary, Licensee may publicly disclose (including to customers or users of the Licensed
Products and to Licensee Providers) that the Action has been settled and that use of the Licensed
Products, in accordance with the terms of this Agreement, is a licensed use. On or shortly after
the Effective Date, the parties will issue a press release substantially in the form shown in
Exhibit C attached hereto.

     12. NOTICES

     Any notice required to be given under this Agreement shall be in writing and delivered
personally to the other Party at the above-stated address or mailed by certified, registered or
express mail, return receipt requested, or by Federal Express, attention CEO or General Counsel.
In the case of NetRatings, a copy of any such notice shall be sent by Federal Express to Seth H.
Ostrow, Esq., Brown Raysman Millstein Felder & Steiner LLP, 900 Third Avenue, New York, New York
10022, Ph. (212) 895-2000. In the case of Licensee, a copy of any such notice shall be sent by
Federal Express to Michael J. Sacksteder, Esq., Fenwick & West LLP, Embarcadero Center West, 275
Battery Street, 16th Floor, San Francisco, California 94111, Ph. (415) 875-2300.

-10-

 

     13. CHOICE OF LAW/JURISDICTION

     This Agreement shall be governed in accordance with the laws of the State of New York. All
disputes under this Agreement shall be resolved by litigation in the appropriate federal or state
courts located in the State of New York, County of New York and the Parties consent to the
exclusive jurisdiction of such courts, agree to accept service of process by mail, and hereby waive
any jurisdictional or venue defenses otherwise available to it in connection with such courts.

     14. ATTORNEYS’ FEES

     In any litigation arising out of this Agreement, the prevailing party shall be entitled to
payment of its reasonable attorneys’ fees and costs by the other party.

     15. CHANGE OF CONTROL EVENT AND ASSIGNABILITY

          15.1 Change of Control Event — With Assignment. In the event of any Change of
Control Event affecting Licensee, then the Additional Royalty required pursuant to Section
3.1(ii)(2) shall be immediately due and payable and shall be paid to NetRatings within thirty
(30) business days of the effective date of the Change of Control Event. In addition to the
foregoing, in the event of a Change of Control Event, if Licensee wishes to assign the Agreement,
including the License to the Purchaser, and provided that all Royalty payments have been paid in
accordance with Section 3.1 and Section 15.1, and provided that Licensee is in all
material respects in compliance with the Agreement, then, upon written notice to NetRatings within
five (5) business days of the effective date of the Change of Control Event, the Agreement,
including the License, may be assigned by Licensee to the Purchaser, subject to the following
limitations:

               (i) the License and any sublicenses granted under this Agreement shall be limited, subject to
the restrictions in Section 15.1(ii), to (1) the Licensed Products commercially released as
of the effective date of the Change of Control Event (“Original Versions”); (2) the elements of
Omniture products which Omniture can show were under development as of the effective date of the
Change of Control Event if such Omniture products are released as standard products within twelve
(12) months of the effective date of the Change of Control Event; (3) future versions of the
Licensed Products commercially released as of the effective date of the Change of Control Event or
other Omniture products identified under Section 15.1(i)(2) which contain no more than
patches to, bug fixes of, minor enhancements or modifications of, or minor updates or upgrades of
the Original Versions except for any new features or functionality added to Original Versions which
infringe a NetRatings Patent that did not already cover the Original Versions; and (4) future
versions of the Licensed Products commercially released as of the effective date of the Change of
Control Event or other Omniture products identified under Section 15.1(i)(2) which
completely replace any Licensed Product or Section 15.1(i)(2) product (e.g., new x.0
release), as evidenced by Omniture or the Purchaser ceasing its distribution of the Licensed
Products or Section 15.1(i)(2) product within three (3) months of the commercial release of
the future version; and

               (ii) following any Change of Control Event, the License and any sublicenses granted under this
Agreement shall not permit combining, merging, bundling or incorporating the Licensed Products, or
any portion thereof, with any of the Purchaser’s Web

-11-

 

Analytics products, services or technology, except if (1) the Purchaser’s Web Analytics
products, services or technology represents less than forty percent (40%) of the source code of the
combined, merged or bundled Web Analytics product (for the avoidance of doubt, if the Purchaser is
not combining, merging, bundling or incorporating a Web Analytics product with a Licensed Product,
then for purposes of this calculation the Licensed Product shall constitute 100% of the source code
of the combined, merged or bundled Web Analytics product); and (2) the Purchaser’s products,
services or technology do not infringe any NetRatings Patent except for NetRatings Patents which
already covered Omniture products, services and/or technology prior to the Change of Control Event.
Except as set forth in the immediately preceding sentence, in the event that any products,
services or technology developed, created or offered by the Purchaser (other than the products,
services or technology which Purchaser acquired from Licensee as a result of the Change of Control
Event), or any portion of such products, services or technology, is bundled with, combined with,
merged with or incorporated into any of the Licensed Products (“Altered Products”), then any such
Altered Products will not be deemed to be Licensed Products under this Agreement and the License
and any sublicenses granted hereunder will not apply to such Altered Products.

          15.2 Assignment. Other than as specifically provided in Section 15.1 herein,
Licensee shall not assign (in whole or in part, directly or indirectly) this Agreement or the
rights and obligations hereunder, including without limitation the License, to any third party
without the prior express written approval of NetRatings. An assignment of this Agreement shall
constitute a material breach of this Agreement. The provisions of the Agreement shall be binding
upon and shall inure to the benefit of the Parties hereto, their heirs, administrators, successors
and assigns, but only to the extent permitted under Section 15.

          15.3 Change of Control Event — Without Assignment. In the event of any Change of
Control Event (in which case the Additional Royalty required pursuant to Section 3.1(ii)(2)
shall be paid to NetRatings within thirty (30) business days of the effective date of the Change of
Control Event) following which Omniture does not assign this Agreement, including the License, to
the Purchaser, the License and any sublicenses granted under this Agreement shall not permit
combining, merging, bundling or incorporating any of the Purchaser’s Web Analytics products,
services or technology, or any portion thereof, with the Licensed Products, and any such altered
products, services or technology will not be deemed to be Licensed Products under this Agreement.
Except as expressly set forth in this Section 15.3, in the event of a Change of Control
Event in which Omniture does not assign this Agreement, this Agreement and the rights and
obligations set forth herein shall remain in full force and effect.

          15.4 Licensee Acquisitions. In the event Licensee acquires an Acquired Entity or the
products, services, technology, customers, or other assets thereof pursuant to Section
3.1(iv), then the products, services, and technology owned by the Acquired Entity will be
considered Licensed Products under this Agreement as of the effective date of such transaction with
the Acquired Entity if and only if, within thirty (30) business days of the effective date of such
acquisition, Licensee pays NetRatings the Licensee Acquisition Royalties, if any, required in
Section 3.1(iv) and provides the royalty statement regarding such Acquired Entity required
under Section 3.5. If Licensee does not timely pay NetRatings the Licensee Acquisition
Royalties, if any, and provide the Section 3.5 royalty statement, then the License granted
in this Agreement shall not extend to any products, services, or technology developed, created or
offered by the Acquired Entity,

-12-

 

including to the extent any products, services or technology developed, created or offered by
the Acquired Entity are incorporated into any of the Licensed Products.

     16. WAIVER

     No waiver by either Party of any default shall be deemed as a waiver of prior or subsequent
default of the same or other provisions of this Agreement.

     17. SEVERABILITY

     If any term, clause or provision hereof is held invalid or unenforceable by a court of
competent jurisdiction, such invalidity shall not affect the validity or operation of any other
term, clause or provision and such invalid term, clause or provision shall be deemed to be severed
from the Agreement.

     18. COUNTERPARTS

     This Agreement may be executed by the Parties in counterparts, which, when assembled, shall be
considered a fully executed original of this Agreement.

     19. SURVIVAL

     The following provisions shall survive the termination or expiration of this Agreement:
Sections 1, 2 (except to the extent the License is terminated in accordance with
Section 10) 3, 4, 6, 7, 8, 10, 11,
12, 13, 14, 17, 19, 20, and 21.

     20. NO ADMISSION

     This Agreement represents a resolution of disputed issues and claims between the Parties.
Nothing contained herein is, or is to be construed as, an admission or evidence of liability on the
part of either Party.

     21. ENTIRE AGREEMENT; AMENDMENT

     This Agreement constitutes the entire understanding of the Parties, and revokes and supersedes
all prior agreements between the Parties and is intended as a final expression of their agreement.
All negotiations and representations made prior to the execution of this Agreement shall be deemed
to have been integrated into the terms and conditions of this Agreement. This Agreement shall not
be modified or amended except in writing signed by the Parties hereto and specifically referring to
this Agreement.

     22. EARLY LICENSEE FAVORABLE TREATMENT

     In addition to, and without limitation of, other consideration exchanged in this Agreement,
NetRatings has entered into this Agreement on the terms and conditions set forth herein in
consideration of (i) the Parties’ reaching a settlement of the Action in its early stages; and (ii)
Licensee’s status as an early licensee.

-13-

 

     IN WITNESS WHEREOF, the Parties hereto, intending to be legally bound hereby, have each caused
this Agreement to be executed by their respective duly authorized representative identified below.

NETRATINGS, INC.

			
	By:	 	/s/ Alan Shapiro
 

			
	Print Name:	 	Alan Shapiro
 

			
	Title:	 	SVP and General Counsel
 

OMNITURE, INC.

			
	By:	 	/s/ Joshua G. James
 

			
	Print Name:	 	Joshua G. James
 

			
	Title:	 	CEO
 

 

 

SCHEDULE A

NETRATINGS PATENTS

	 	 	 
	Patent/Publication	 	 
	No.	 	Title
	5,675,510

	 	Computer Use Meter and Analyzer
	6,115,680

	 	Computer Use Meter and Analyzer
	AU0701813

	 	Computer Use Meter and Analyzer
	BR9609217

	 	Medidor E Analizador De Uso De Computador
	CA2223919

	 	Computer Use Meter and Analyzer
	EP0843946

	 	Rechnerbenutzungsmesser Und Analysator
	JP03317705
	 	 
	MX193614
	 	 
	NO09705728

	 	Maaler Og Analysator For Datamaskinbenyttelse
	WO9641495

	 	Computer Use Meter and Analyzer
	 
	 	 
	6,108,637

	 	Content Display Monitor
	AU735285

	 	Content Display Monitor
	CA2246746

	 	Content Display Monitor
	CN1174316

	 	Content Display Monitor
	CN1547123

	 	Content Display Monitor
	CN1547124

	 	Content Display Monitor
	CN1209891

	 	Content Display Monitor
	DK870234

	 	Overvaagning Af Fremvisning Af Indhold
	EP0870234

	 	Content Display Monitor
	EP1130526

	 	Content Transferring System
	EP1168196

	 	Content Transferring Method
	DE69720186

	 	Inhaltsanzeigemonitor
	ES2195170

	 	Monitor De Exhibicion De Contenido
	US20040078292

	 	Content Display Monitoring By A Processing System
	WO9810349

	 	Content Display Monitor
	 
	 	 
	5,796,952

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource And Creating Client Profiles And Resource Database
	6,138,155

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource And Creating Client Profiles And Resource Database
	6,643,696

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource And Creating Client Profiles And Resource Database
	6,763,386

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource Downloaded From A Server
	AU727170

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource And Creating Client Profiles And Resource Database

 

 

	 	 	 
	Patent/Publication	 	 
	No.	 	Title
	BR9808033

	 	Processo E Aparelho Para Rastreamento De Interacao De Cliente Com Um Recurso De Rede E Criacao De Perfis De Cliente E Recurso De Base De Dados
	CA2284530

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource And Creating Client Profiles And Resource Database
	CN1251669

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource And Creating Client Profiles And Resource Database
	EP1010116

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource And Creating Client Profiles And Resource Database
	IL131871

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource And Creating Client Profiles And Resource Database
	JP2000514942
	 	 
	KR341110
	 	 
	NZ337756

	 	Method and apparatus for tracking client interaction with a network resource and creating client profiles and resource database
	US20050114511

	 	Method And Apparatus For Tracking Client Interaction With a Network Resource
	US20040221033

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource And Creating Client Profiles And Resource Database
	WO9843380

	 	Method And Apparatus For Tracking Client Interaction With A Network Resource And Creating Client Profiles And Resource Database

-2-

 

SCHEDULE B

LICENSED PRODUCTS

SiteCatalyst

Omniture Discover

Omniture SearchCenter

Omniture DataWarehouse

Omniture University

Omniture Best Practices

 

 

SCHEDULE C

OMNITURE PATENTS

[ * ]

 

 

SCHEDULE D

ROYALTY STATEMENT

	 	 	 	 	 
	Licensee Revenue for Calendar Year 2___:
	 	$	                                        	 
	 
	 	 	 	 
	Additional Royalty Payment
	 	$	                                        	 
	 
	 	 	 	 
	Licensee Revenue for Calendar Year 2___ from each Licensee Provider listed in

Schedule F that exceeded twenty-five percent (25%) of all Licensee Revenue:
	 
	 	 	 	 
	Licensee Provider Royalty Payment:
	 	$	                                        	 

 

 

SCHEDULE F

[ * ]

-2-

 

EXHIBIT A

STIPULATION OF DISMISSAL

WITH PREJUDICE

 

 

UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF DELAWARE

	 	 	 	 	 	 
	 
	 	 	)	 	 
	 
	 	 	)	 	 
	 
	 	 	)	 	 
	NETRATINGS, INC.,
	 	 	)	 	 
	 
	 	 	)	 	Civil Action No. 05-313-GMS
	Plaintiff,
	 	 	)	 	 
	 
	 	 	)	 	 
	vs.
	 	 	)	 	STIPULATION AND
	 
	 	 	)	 	ORDER OF DISMISSAL
	OMNITURE, INC.,
	 	 	)	 	WITH PREJUDICE
	 
	 	 	)	 	 
	Defendant.
	 	 	)	 	 

     Plaintiff NetRatings, Inc. (“NetRatings”), by its counsel Brown Raysman Millstein Felder &
Steiner LLP, and Defendant Omniture, Inc. (“Omniture”), by its counsel Fenwick & West, LLP, hereby
stipulate that they have reached a confidential settlement of the dispute that is the subject
matter of the above-referenced action (the “Action”). Based upon such settlement, and upon the
consent and approval of NetRatings and Omniture as indicated herein, IT IS HEREBY ORDERED, ADJUDGED
AND DECREED that:

     1. The Action, including, without limitation, all claims and counterclaims asserted in the
Action, is hereby dismissed with prejudice as to all parties pursuant to Rule 41(a)(l)(ii)
of the Federal Rules of Civil Procedure.

     2. Each party shall bear its own costs and attorneys fees.

 

 

	 	 	 	 	 	 	 	 	 
	AGREED TO AND ACCEPTED:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Date:	 	 	 	Date:
	 
	 	 	 	 	 	 	 	 
	Counsel for NetRatings, Inc.	 	 	 	Counsel for Omniture, Inc.
	 
	 	 	 	 	 	 	 	 
	BROWN RAYSMAN MILLSTEIN	 	 	 	FENWICK & WEST LLP
	FELDER & STEINER LLP	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	By:	 	 
	 

	 	 

Frederick L.Whitmer (FW 8888)
	 	 	 	 	 	 

Michael Sacksteder (                    )
	 

	 	Seth H. Ostrow (SO 9605)
	 	 	 	 	 	Heather Mewes (                    )
	 

	 	Arianna Frankl (AF 7764)	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	900 Third Avenue	 	 	 	Embarcadero Center West
	New York, New York 10022	 	 	 	275 Battery St., 16thFl.
	Telephone: (212) 895-2000	 	 	 	San Francisco, California 94111
	Facsimile: (212) 895-2900	 	 	 	Telephone: (415) 875-2300
	 	 	 	 	 	 	Facsimile: (415) 281-1350
	 
	 	 	 	 	 	 	 	 
	YOUNG CONAWAY STARGATT	 	 	 	RICHARDS, LAYTON & FINGER
	& TAYLOR, LLP	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	By:	 	 
	 

	 	 

John W. Shaw (#3362)
	 	 	 	 	 	 

William J. Wade (#704)
	 
	 	 	 	 	 	 	 	 
	The Brandywine Building	 	 	 	One Rodney Square
	1000 West Street, 17th Floor	 	 	 	920 N. King Street
	Wilmington, Delaware 19801	 	 	 	P.O. Box 551
	Telephone: (302) 571-6600	 	 	 	Wilmington, Delaware 19899
	Facsimile: (302) 571-1253	 	 	 	Telephone: (302) 651-7700
	 	 	 	 	 	 	Facsimile: (302) 651-7701
	 
	 	 	 	 	 	 	 	 
	SO ORDERED:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	Date
	 	 	 	 	 	 	 	 
	 	 	 
	 	 	 	 

GREGORY M. SLEET
	 	 	 	 	 	 	UNITED STATES DISTRICT JUDGEexv10w10

 

Exhibit 10.10

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD, PLEDGED, OR OTHERWISE TRANSFERRED WITHOUT AN
EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR PURSUANT TO RULE 144 OR AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO THE CORPORATION AND ITS COUNSEL, THAT SUCH REGISTRATION IS NOT REQUIRED.

WARRANT TO PURCHASE STOCK

	 	 	 
	Corporation:

	 	 MyComputer.com, Inc., a Delaware Corporation
	 
	 	 
	Number of Shares:

	 	 490,990
	 
	 	 
	Class of Stock:

	 	Common Stock
	 
	 	 
	Initial Exercise Price:

	 	 $0.20 per share
	 
	 	 
	Issue Date:

	 	 March 26, 2002
	 
	 	 
	Expiration Date:

	 	 March 26, 2012

     This Warrant certifies that, for good and valuable consideration, NetObjects, Inc., a Delaware
corporation (“Holder”), is entitled to purchase from the corporation named above (the “Company”),
on or after March 31, 2004, but only if the Company has paid all three Scheduled Payments pursuant
to that certain Settlement and Payoff Agreement, dated the date hereof, by and between the Holder
and the Company, until 5:00 p.m. Pacific time, on the Expiration Date set forth above, the number
of fully paid and nonassessable shares of the class of stock (the “Shares”) of the Company at the
initial exercise price per Share (the “Warrant Price”), all as set forth above and as adjusted
pursuant to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions
set forth in this Warrant.

     1. EXERCISE.

          1.1 Method of Exercise. Holder may exercise this Warrant by delivering a duly
executed Notice of Exercise in substantially the form attached as Exhibit A to the
principal office of the Company. Unless Holder is exercising the conversion right set forth in
Section 1.2, this Warrant may be exercised in whole or in part and Holder shall also deliver to the
Company a check or wire transfer for the aggregate Warrant Price for the Shares being purchased.
Notwithstanding the foregoing sentence, Holder may, and the Company shall permit Holder to, apply
any indebtedness owed by the Company to Holder (including any amounts owed under the
above-referenced Settlement and Payoff Agreement) towards payment of the aggregate Warrant Price.

          1.2 Net Exercise Election. The Holder may elect to convert all or a portion of this
Warrant, without the payment by the Holder of any additional consideration, by the surrender of
this Warrant or such portion of this Warrant to the Company, with the net exercise election
selected in the Notice of Exercise attached hereto as Exhibit A duly executed by the
Holder, into up to the number of Shares that is obtained under the following formula:

 

 

X = Y (A-B)

A

	 	 	 	 	 
	Where:

	 	X =
	 	the number of Shares to be issued to the Holder pursuant to this Section 1.2.
	 
	 	 	 	 
	 

	 	Y =
	 	the number of Warrant Shares as to which this Warrant is then being net
exercised.
	 
	 	 	 	 
	 

	 	A =
	 	the fair market value of one Share, as determined in good faith by the
Company’s Board of Directors, as at the time the net exercise election is
made pursuant to this Section 1.2.
	 
	 	 	 	 
	 

	 	B =
	 	the Warrant Price.

For purposes of the above calculation, fair market value of one Share shall be determined by the
Company’s Board of Directors in good faith; provided, however, that where there
exists a public market for the Company’s Common Stock at the time of such exercise, the fair market
value per share shall be the product of (i) the average of the closing bid and asked prices of the
Common Stock quoted in the Over-The-Counter Market Summary or the last reported sale price of the
Common Stock or the closing price quoted on the Nasdaq National Market or on any exchange on which
the Common Stock is listed, whichever is applicable, as published in the Western Edition of The
Wall Street Journal for the five (5) trading days prior to the date of determination of fair market
value and (ii) the number of shares of Common Stock into which each Share is convertible, if
applicable, at the time of such exercise. Notwithstanding the foregoing, in the event the Warrant
is exercised in connection with the Company’s initial public offering of Common Stock, the fair
market value per share shall be the per share offering price to the public of the Company’s initial
public offering. The Company will promptly respond in writing to an inquiry by the Holder as to
the then current fair market value of one Share.

          1.3 Delivery of Certificate and New Warrant. Promptly after Holder exercises this
Warrant, the Company shall deliver to Holder certificates for the Shares acquired and, if this
Warrant has not been fully exercised or converted and has not expired, this Warrant shall
automatically be reduced by the number of Shares issued and remain exercisable for such remaining
Shares not so acquired, and all other terms of the Warrant shall otherwise remain in full force and
effect as so adjusted. Upon final exercise of this Warrant for any such remaining number of
Shares, this Warrant shall be surrendered by the Holder to the Company for cancellation.

          1.4 Replacement of Warrants. On receipt of evidence reasonably satisfactory to the
Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss,
theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and
amount to the Company or, in the case of mutilation, or surrender and cancellation of this Warrant,
the Company at its expense shall execute and deliver, in lieu of this Warrant, a new warrant of
like tenor.

-2-

 

          1.5 Sale, Merger, Consolidation or Liquidation of the Company.

                1.5.1 Acquisition. For the purpose of this Warrant, “Acquisition” means (a) any sale
or exchange of the capital stock by the stockholders of the Company in one transaction or series of
related transactions where more than 50% of the outstanding voting power of the Company is acquired
by a person or entity or group of related persons or entities; or (b) any reorganization,
consolidation or merger of the Company where the outstanding voting securities of the Company
immediately before the transaction represent or are converted into less than fifty percent 50% of
the outstanding voting power of the surviving entity (or its parent corporation) immediately after
the transaction; or (c) the consummation of any transaction or series of related transactions that
results in the sale of all or substantially all of the assets of the Company, followed by the
distribution of the proceeds to the Company’s stockholders.

                1.5.2 Survival of Warrant. If the price or exchange value offered per share of Common
Stock in an Acquisition (the “Acquisition Value”) is less than the Warrant Price then in effect, as
a part of such Acquisition, lawful provision shall be made so that Holder shall thereafter be
entitled to receive upon exercise of this Warrant, during the period specified in this Warrant and
upon payment of the Warrant Price then in effect, the number of shares of stock or other securities
or property of the Company, or of the successor corporation resulting from such Acquisition, to
which a holder of the Common Stock deliverable upon exercise of this Warrant would have been
entitled in such Acquisition if this Warrant had been exercised immediately before that
Acquisition. In any such case, appropriate adjustment shall be made in the application of the
provisions of this Warrant with respect to the rights and interests of Holder after the Acquisition
to the end that the provisions of this Warrant (including adjustment of the Warrant Price then in
effect and number of shares purchasable upon exercise of this Warrant) shall be applicable after
that Acquisition, as near as reasonably may be, in relation to any shares or other property
deliverable after that Acquisition upon exercise of this Warrant.

                1.5.3 Termination of Warrant. Prior to the closing of any Acquisition, the Company
shall give Holder at least thirty (30) days advance written notice of such event (the “Company
Notice”), which notice shall include the Company’s best estimate of the value of the Shares
receivable upon exercise or conversion of this Warrant and the proposed date upon which such event
is expected to occur. Notwithstanding anything to the contrary contained herein, during such
notice period, Holder may exercise or convert this Warrant in accordance with its terms, whether or
not exercise or conversion is contingent upon the happening of such event and/or existence of a
minimum value of the Shares receivable upon exercise or conversion as provided on Holder’s exercise
notice; provided that such minimum value shall be no greater than the per share price set forth in
the Company Notice. Subject to any prior exercise or conversion as provided in the preceding
sentence, this Warrant will terminate with respect to the Shares so exercised or converted and in
any event if the Acquisition Value is more than the Warrant Price in effect, at 5:00 p.m. Pacific
time on the day prior to the date such event is expected to occur as set forth in the Company
Notice; provided that (a) the Company Notice of the proposed event is actually received by Holder,
as evidenced by a return receipt of certified mail delivery, a certificate of delivery by hand
delivery or written verification of delivery from the overnight courier, and (b) the event actually
occurs

-3-

 

          within thirty (30) days after the date it is expected to occur, as such date was specified in
the Company Notice.

     2. ADJUSTMENTS TO THE SHARES.

          2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on the
outstanding shares of the Company’s Common Stock payable in shares of the Company’s Common Stock or
other securities of the Company or subdivides or combines the outstanding shares of the Company’s
Common Stock, then upon exercise or conversion of this Warrant, unless, in case this Warrant is
exercisable into shares of the Company’s Preferred Stock and the conversion ratio of such Preferred
Stock already reflects such event for each Share acquired, Holder shall receive, without cost to
Holder, the total number and kind of securities to which Holder would have been entitled had Holder
owned the Shares of record as of the date the dividend, subdivision or combination occurred.

          2.2 Reclassification, Exchange or Substitution. Upon any reclassification, exchange,
substitution, or other event that results in a change of the number and/or class of the securities
issuable upon exercise or conversion of this Warrant (other than a merger, consolidation or
recapitalization described in Section 1.5 above or a stock dividend, split, etc. described in
Section 2.1 above), Holder shall be entitled to receive, upon exercise or conversion of this
Warrant, the number and kind of securities and property that Holder would have received for the
Shares if this Warrant had been exercised immediately before such reclassification, exchange,
substitution or other event. By way of example, such an event shall include any automatic
conversion of the outstanding or issuable securities of the Company of the same class or series as
the Shares to Common Stock pursuant to the terms of the Company’s Certificate of Incorporation upon
the closing of a registered public offering of the Company’s Common Stock. The Company or its
successor shall promptly issue to Holder a new Warrant for such new securities or other property.
The new Warrant shall provide for adjustments which shall be as nearly equivalent as may be
practicable to the adjustments provided for in this Section 2 including, without limitation,
appropriate adjustments to the Warrant Price and to the number of securities or property issuable
upon exercise or conversion of the new Warrant.

          2.3 Adjustments of Warrant Price. If the outstanding Shares are combined or
consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price
shall be proportionately increased. If the outstanding Shares are divided by reclassification or
otherwise, into a greater number of shares, the Warrant Price shall be proportionately decreased.

          2.4 Adjustment is Cumulative. The provisions of this Section 2 shall similarly apply
to successive, stock dividends, stock spits or combinations, reclassifications, exchanges,
substitutions, or other events.

          2.5 No Impairment. The Company shall not, by amendment of its Certificate of
Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution,
issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed under this Warrant by the Company,
but shall at all times in good faith assist in carrying out of all the provisions of this Section 2
and in

-4-

 

taking all such action as may be necessary or appropriate to protect Holder’s rights under
this Section against impairment.

          2.6 Fractional Shares. No fractional Shares shall be issuable upon exercise or
conversion of the Warrant and the number of Shares to be issued shall be rounded down to the
nearest whole Share. If a fractional share interest arises upon any exercise or conversion of the
Warrant, the Company shall eliminate such fractional Share interest by paying Holder an amount by
check computed by multiplying the fractional interest by the fair market value of a full Share.

          2.7 Certificate as to Adjustments. Upon each adjustment of the Warrant Price, the
Company at its expense shall compute such adjustment, and furnish Holder with a certificate of its
Chief Financial Officer setting forth such adjustment and the facts upon which such adjustment is
based. The Company shall, upon written request, furnish Holder a certificate setting forth the
Warrant Price in effect upon the date thereof and the series of adjustments leading to such Warrant
Price.

     3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

          3.1 Representations and Warranties. The Company hereby represents and warrants to the
Holder that all Shares which may be issued upon the exercise of the purchase right represented by
this Warrant, and all securities, if any, issuable upon conversion of the Shares, shall, upon
issuance, be duly authorized, validly issued, fully paid and nonassessable, and free of any liens
and encumbrances except for restrictions on transfer provided for herein or under applicable
federal and state securities laws. The Company hereby represents and warrants to the Holder that
the Capitalization Table of the Company attached hereto as Exhibit B is true and correct as
of the date hereof.

     4. REPRESENTATIONS OF HOLDER: TRANSFER.

          4.1 Representations. Holder hereby represents and warrants to the Company as follows.
Holder is a sophisticated investor having such knowledge and experience in business and investment
matters that Holder is capable of protecting Holder’s own interests in connection with the
acquisition, exercise or disposition of this Warrant. Holder is aware that this Warrant and the
Shares are being, or will be, issued to Holder in reliance upon Holder’s representation in this
Section 4 and that such securities are restricted securities that cannot be publicly sold except in
certain prescribed situations. Holder is aware of the provisions of Rule 144 promulgated under the
Act and of the conditions under which sales may be made thereunder. Holder has received such
information about the Company as Holder deems reasonable, has had the opportunity to ask questions
and receive answers from the Company with respect to its business, assets, prospects and financial
condition and has verified any answers Holder has received from the Company with independent third
parties to the extent Holder deems necessary. The Holder of this Warrant, by acceptance hereof,
acknowledges this Warrant and the Shares to be issued upon exercise hereof or conversion thereof
are being acquired solely for the Holder’s own account and not as a nominee for any other party,
and for investment, and that the Holder will not offer, sell or otherwise dispose of this Warrant
or any Shares to be issued upon exercise hereof or conversion thereof except under circumstances
that will not result in a violation of the Act or any state securities laws.

-5-

 

          4.2 Legends. This Warrant and the Shares (and the securities issuable, directly or
indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in
substantially the following form:

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
STATE SECURITIES LAW AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN
EFFECTIVE REGISTRATION THEREOF UNDER SUCH ACT OR LAW OR PURSUANT TO RULE 144 AND ANY STATE
EXEMPTION FROM REGISTRATION OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
CORPORATION AND ITS COUNSEL THAT SUCH REGISTRATION NOT REQUIRED.

          4.3 Compliance with Securities Laws on Transfer. This Warrant and the Shares issuable
upon exercise this Warrant (and the securities issuable, directly or indirectly, upon conversion of
the Shares, if any) may not be transferred or assigned in whole or in part without compliance with
applicable federal and state securities laws by the transferor and the transferee (including,
without limitation, the delivery of investment representation letters and legal opinions reasonably
satisfactory to the Company, as reasonably requested by the Company). The Company shall not
require Holder to provide an opinion of counsel if (a) the transfer is to the stockholders or
constituent partners of Holders by way of dividend or distribution to all of the same or (b) there
is no material question as to the availability of current information as referenced in Rule 144(c),
Holder represents that it has complied with Rule 144(d) and (e) in reasonable detail, the selling
broker represents that it has complied with Rule 144(f), and the Company is provided with a copy of
Holder’s notice of proposed sale and/or transfer.

          4.4 Transfer Procedure. Subject to the provisions of Section 4.3, Holder may transfer
all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities
issuable, directly or indirectly, upon conversion of the Shares, if any) by giving the Company a
written notice of the portion of the Warrant being transferred, such notice setting forth the name,
address and taxpayer identification number of the transferee, and surrendering this Warrant to the
Company for reissuance to the transferee(s) (and to the new Warrant Holder for any remaining
Shares, if applicable).

          4.5 Market Standoff. The Holder agrees in connection with any registration of the
Company’s securities under the Act that, upon the request of the Company or the underwriters
managing any registered public offering of the Company’s securities, Holder will not sell or
otherwise dispose of any Shares or any other securities of the Company without the prior written
consent of the Company or such managing underwriters, as the case may be, for a period of time (not
to exceed one hundred eighty (180) days) after the effective date of such registration requested by
such managing underwriters subject to all restrictions as the Company or the managing underwriters
may specify generally. Holder further agrees to enter into any agreement reasonably required by
the underwriters to implement the foregoing.

     In order to enforce the foregoing covenant, the Company shall have the right to place
restrictive legends on the certificates representing the Shares subject to this Section and to
impose stop transfer instructions with respect to such Shares of Holder until the end of such
period.

-6-

 

     5. GENERAL PROVISIONS.

          5.1 Notices. Any and all notices required or permitted to be given to a party
pursuant to the provisions of this Warrant will be in writing and will be effective and deemed to
provide such party sufficient notice under this Warrant on the earliest of the following: (i) at
the time of personal delivery, if delivery is in person; (ii) at the time of transmission by
facsimile, addressed to the other party at its facsimile number specified herein (or hereafter
modified by subsequent notice to the parties hereto), with confirmation of receipt made by both
telephone and printed confirmation sheet verifying successful transmission of the facsimile; (iii)
one (1) business day after deposit with an express overnight courier for United States deliveries,
or two (2) business days after such deposit for deliveries outside of the United States, with proof
of delivery from the courier requested; or (iv) three (3) business days after deposit in the United
States mail by certified mail (return receipt requested) for United States deliveries.

          All notices for delivery outside the United States will be sent by facsimile or by express
courier. All notices not delivered personally or by facsimile will be sent with postage and/or
other charges prepaid and properly addressed to the party to be notified at the address or
facsimile number set forth below the signature lines to this Warrant, or at such other address or
facsimile number as such other party may designate by one of the indicated means of notice herein
to the other parties hereto. Notices to the Company will be marked “Attention: President”.
Notices by facsimile shall be machine verified as received.

          5.2 Waiver. This Warrant and any term hereof may be changed, waived, discharged or
terminated only by an instrument in writing signed by the party against which enforcement of such
change, waiver, discharge or termination is sought.

          5.3 Attorneys Fees. In the event of any dispute between the parties concerning the
terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to
collect from the other party all costs incurred in such dispute, including reasonable attorneys’
fees.

          5.4 Governing Law. This Warrant will be governed by and construed in accordance with
the laws of the State of California, without giving effect to that body of laws pertaining to
conflict of laws.

          5.5 Further Assurances. The parties agree to execute such further documents and
instruments and to take such further actions as may be reasonably necessary to carry out the
purposes and intent of this Warrant.

          5.6 Titles and Headings. The titles, captions and headings of this Warrant are
included for ease of reference only and will be disregarded in interpreting or construing this
Warrant. Unless otherwise specifically stated, all references herein to “sections” and “exhibits”
will mean “sections” and “exhibits” to this Warrant.

          5.7 Counterparts. This Warrant may be executed in any number of counterparts, each of
which when so executed and delivered will be deemed an original, and all of which together shall
constitute one and the same agreement.

-7-

 

          5.8 Severability. If any provision of this Warrant is determined by any court or
arbitrator of competent jurisdiction to be invalid, illegal or unenforceable in any respect, such
provision will be enforced to the maximum extent possible given the intent of the parties hereto.
If such clause or provision cannot be so enforced, such provision shall be stricken from this
Warrant and the remainder of this Warrant shall be enforced as if such invalid, illegal or
unenforceable clause or provision had (to the extent not enforceable) never been contained in this
Warrant. Notwithstanding the forgoing, if the value of this Warrant based upon the substantial
benefit of the bargain for any party is materially impaired, which determination as made by the
presiding court or arbitrator of competent jurisdiction shall be binding, then both parties agree
to substitute such provision(s) through good faith negotiations.

          5.9 Facsimile Signatures. This Warrant may be executed and delivered by facsimile and
upon such delivery the facsimile signature will be deemed to have the same effect as if the
original signature had been delivered to the other party.

          5.10 Amendment and Waivers. This Warrant may be amended only by a written agreement
executed by each of the parties hereto. No amendment of or waiver of, or modification of any
obligation under this Warrant will be enforceable unless set forth in a writing signed by the party
against which enforcement is sought. Any amendment effected in accordance with this section will
be binding upon all parties hereto and each of their respective successors and assigns. No delay
or failure to require performance of any provision of this Warrant shall constitute a waiver of
that provision as to that or any other instance. No waiver granted under this Warrant as to any
one provision herein shall constitute a subsequent waiver of such provision or of any other
provision herein, nor shall it constitute the waiver of any performance other than the actual
performance specifically waived.

          5.11 Entire Agreement. This Warrant and the documents referred to herein constitute
the entire agreement and understanding of the parties with respect to the subject matter of this
Warrant, and supersede all prior understandings and agreements, whether oral or written, between or
among the parties hereto with respect to the specific subject matter hereof.

-8-

 

WARRANT HOLDER:

NETOBJECTS, INC.

	 	 	 
	By:

	 	/s/ illegible
	 

	 	 

	 	 	 
	Name:

	 	Name illegible
	 

	 	 

	 	 	 
	Title:

	 	Director
	 

	 	 

	 	 	 
	Address:

	 	301 Galveston Drive
	 

	 	 
	 

	 	Redwood City, CA 94063
	 

	 	 

	 	 	 
	Attention to:

	 	Michael Zisman
	 

	 	 

	 	 	 
	Facsimile:

	 	650-482-3600
	 

	 	 

COMPANY:

MYCOMPUTER.COM, INC.

	 	 	 
	By:

	 	/s/ Joshua G. James
	 

	 	 

	 	 	 
	Name:

	 	Joshua G. James
	 

	 	 

	 	 	 
	Title:

	 	CEO
	 

	 	 

	 	 	 
	Address:

	 	1358 W. Business Park Drive
	 

	 	 
	 

	 	Orem, UT 84058
	 

	 	 

	 	 	 
	Attention to:

	 	Joshua James, CEO and President
	 

	 	 

	 	 	 
	Facsimile:

	 	801-722-7001
	 

	 	 

 

 

EXHIBIT A

NOTICE OF EXERCISE

(TO BE SIGNED ONLY UPON EXERCISE OF WARRANT)

     The undersigned hereby elects to purchase                     shares of the Common Stock (the
“Shares”) of MyComputer.com, Inc., a Delaware corporation, pursuant to the terms of the attached
Warrant to Purchase Stock with an Issue Date of March 26, 2002 (the “Warrant”), as follows:

(Initial applicable method:)

	 	 	 
	      a.

	 	The undersigned tenders herewith payment of the total purchase
price of such Shares in full, pursuant to a check or wire transfer,
in the amount of $                    ;
	 
	 	 
	 

	 	OR
	 
	 	 
	     b.

	 	This exercise or conversion     [is]     [is not] contingent upon
the closing of the Acquisition or other event specified in the
Company Notice to Holder in accordance with Section 1.5 of the
Warrant received by Holder on                      and      [is]
     [is not] contingent upon a sale price or fair market value for
the Company’s Common Stock in the Acquisition or other event of no
less than the lesser of (a) $                    per share or (b) the per
share price set forth in the Company Notice.
	 
	 	 
	 

	 	OR
	 
	 	 
	     c.

	 	The undersigned hereby elects to convert the Warrant into Shares by
the net exercise election pursuant to Section 1.2 of the Warrant.
This conversion is exercised with respect to                     shares of
Common Stock covered by the Warrant resulting in a net total of
                    Shares being issued to the undersigned.

     Please issue a certificate or certificates representing said Shares in the name of the
undersigned. The undersigned represents that it is acquiring the shares solely for its own account
and not as a nominee for any other party and not with a view toward the resale or distribution
thereof except in compliance with applicable securities laws and hereby repeats the representations
and warranties of the undersigned that are set forth in Section 4.1 of the attached Warrant.

 

 

(Printed Name of Holder)

 

 

 

Address:

 

(Signature of Holder)

 

 

EXHIBIT B

[OMITTED]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00103-of-00352.parquet"}]]